Clinical Trial

MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2024 (before its estimated March 2025 completion). Its status may not reflect the trial's current state.
Summary
This phase III trial aims to compare the efficacy and safety of MIL62 combined lenalidomide and lenalidomide alone to treat patient diagnosed with Follicular Lymphoma (FL) and refractory to rituximab. The study randomized patients with a 1:1 ratio to receive either MIL62 plus lenalidomide or lenalidomide.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-04-05; most recent amendment 2024-11-19.
Status change: Not Yet Recruiting → Recruiting 2022-02-13
Trial Details
NCT Number NCT04834024
Lead Sponsor Beijing Mabworks Biotech Co., Ltd.
Conditions Follicular Lymphoma and Marginal Zone Lymphoma
Enrollment 168 participants
Start Date 2021-06-02
Primary Completion 2025-03 (estimated)
Study Completion 2025-03 (estimated)
Updated on ClinicalTrials.gov 2024-11-20